Chemistry:Rivoglitazone
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H19N3O4S |
Molar mass | 397.45 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]
It is being developed by Daiichi Sankyo.
References
- ↑ "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Current Opinion in Investigational Drugs 8 (4): 338–344. April 2007. PMID 17458185.
- ↑ "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes, Obesity & Metabolism 13 (9): 806–813. September 2011. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.
Original source: https://en.wikipedia.org/wiki/Rivoglitazone.
Read more |